Depomed (DEPO) Tops Q3 EPS by 3c, Revenue Comes in Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St futures fall as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Musk rules out TSMC role in Terafab operations; Intel gains
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
Tweet
Share
E-mail
Get Alerts DEPO Hot Sheet
Price: $7.30 --0%
Financial Fact:
Research and development expense: 10.41M
Today's EPS Names:
AEHR, VFS, CMTL, More
Financial Fact:
Research and development expense: 10.41M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Depomed (NASDAQ: DEPO) reported Q3 EPS of $0.14, $0.03 better than the analyst estimate of $0.11. Revenue for the quarter came in at $95 million versus the consensus estimate of $99.57 million.
GUIDANCE:
Depomed sees FY2017 revenue of $375-380 million, versus the consensus of $393.6 million.
For earnings history and earnings-related data on Depomed (DEPO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Constellation Brands (STZ) Beats Q2 EPS by 13c, Revenue Beats, Offers Guidance
- Penguin Solutions (PENG) Tops Q4 EPS by 23c, Offers Guidance
- Why Barclays says the bull market is "running on tighter margins"
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
